Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vipivotide Tetraxetan SCHEMBL18040251 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL20180896 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21881849 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729006 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21316439 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24612683 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL22313039 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729005 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21501570 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL29648484 | 1.00 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| EP-3634965-B1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-02-22 | — | — | EP | disclosed |
| US-20220125957-A1 | METHODS OF TREATING CANCER | SATHEKGE MIKE (ZA) | 2022-04-28 | — | — | US | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2021-04-13 | — | — | US | disclosed |
| US-20200095257-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2020061293-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061458-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125957-A1 | METHODS OF TREATING CANCER | PAICS, FOLH1, INHA | FOLH1 2/4885 |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | FOLH1 3/4885 |
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | FOLH1 1/4885 |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | FOLH1 10/4885 |
| US-20200095257-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | SLC30A5, SLC40A1, FOLH1 | FOLH1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.